Clinical trials: Salivary Gland Tumor
Cancer
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
RATIONALE: Suberoylanilide hydroxamic acid may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
- Trial name
- NCT00045006
- Testing
- vorinostat
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Head and Neck Carcinoma, Adenoid Cystic Carcinoma
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non…
- Conditions
- Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT03556228
- Testing
- VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg)
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 242 people
- Sponsor
- VM Oncology, LLC
Xerostomia Due to Radiotherapy (Disorder)
Screening of Biomarkers and Related Mechanisms for RIX
A large number of patients undergoing radiotherapy and chemotherapy are suffering from dry mouth. Due to reduced saliva secretion, patients may experience symptoms such as difficulty chewing and swallowing.
- Trial name
- RIX (NCT06700863)
- Testing
- Radiation Therapy
- Where
- 4 sites in China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Head and Neck Cancer
Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer
RATIONALE: Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00004163
- Testing
- Trastuzumab
- Where
- 10 sites in United States
- Volunteers
- 14 people
- Sponsor
- Dana-Farber Cancer Institute
Cancer of the Head and Neck, Xerostomia
The Effectiveness of a Thyme and Honey Spray for Oral Toxicities
Aim: To evaluate the effectiveness of thymus honey on radiation induced-oral mucositis and xerostomia. Background: Oral mucositis and xerostomia are two of the most severe side effects that head and neck cancer patients confront…
- Conditions
- Cancer of the Head and Neck, Xerostomia, Oral Mucositis, Radiation Toxicity
- Trial name
- HONEY (NCT04880148)
- Testing
- Thyme and Honey-based oral spray
- Where
- 2 sites in Cyprus
- Volunteers
- 200 people
- Sponsor
- Cyprus University of Technology
Salivary Gland Cancer, Adenoid Cystic Carcinoma of the Salivary Gland
Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers
This research study is studying the effect of different drugs as possible treatments for salivary and other head and neck cancers/ The name of the study intervention involved in this study is: -- implantable microdevice
- Conditions
- Salivary Gland Cancer, Adenoid Cystic Carcinoma of the Salivary Gland, Squamous Cell Carcinoma of Head and Neck, Head and Neck Cancer
- Trial name
- NCT05553782
- Testing
- Implantable Microdevice (IMD)
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Brigham and Women's Hospital
HNSCC
Dose-Effect Relation of Salivary Gland Irradiation
Optimization of radiotherapy to reduce xerostomia is difficult, because many gland locations cannot be seen with current imaging modalities and biological dose-effect are currently insufficiently understood.
- Trial name
- NCT03367780
- Testing
- PSMA PET/CT-scan
- Where
- 3 sites in Netherlands
- Volunteers
- 32 people
- Sponsor
- The Netherlands Cancer Institute
Thyroid Cancer, Salivary Gland Cancer
Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors
Phase II, 2-cohort, single arm trial treated with the combination of the following two agents: 1. Pembrolizumab (MK3475) 200mg, every three weeks, iv 2. Docetaxel 75mg/m2, every three weeks, iv
- Trial name
- iPRIME (NCT03360890)
- Testing
- Pembrolizumab, Docetaxel
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Chicago
Comparison of Salivary Paxillin Levels in OPMLs and OSCC to Healthy Subjects
Evaluation of the Levels of Salivary Paxillin Oral Premalignant and Malignant Lesions
This investigation was carried out to analyze and compare the salivary paxillin levels between oral premalignant and malignant lesions (OPMLs), OSCC and the healthy controls in order to assess its potential role as a biomarker of…
- Trial name
- NCT06154551
- Testing
- Paxillin biomarker
- Where
- Egypt
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Cairo University
Head and Neck Cancer
Everolimus and Docetaxel in Treating Patients With Recurrent, Locally Advanced, or Metastatic Head and Neck Cancer
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- DORA (NCT01313390)
- Testing
- docetaxel, everolimus, laboratory biomarker analysis
- Where
- United Kingdom
- Volunteers
- 4 people
- Sponsor
- University College, London
Xerostomia Following Radiotherapy, Xerostomia Following in Neck or Head After Cancer Surgery
Does Craniosacraltherapy Combined With Exercises That Focuses om Respiration and Posture in the Upper Body Have an Effect on Xerostomia and Other Late Sequelae on People Who Has Been Suffering From Cancer in Mouth and Throat?
The current study aims to assess the efficacy of manual treatment with craniosacral therapy of fascial tissue in throat, neck, cranial and mouth region, on radiation and/or surgery-induced salivary gland hypofunction and…
- Conditions
- Xerostomia Following Radiotherapy, Xerostomia Following in Neck or Head After Cancer Surgery, Other Late Sequelae Following Radiotherapy and Cancer Surgery in Neck or Head
- Trial name
- NCT05882890
- Testing
- Craniosacral Therapy, Exercices Targeting Upper Posture and Respiration
- Where
- 2 sites in Denmark
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Cathrine Rahbek
Head and Neck Cancer, Lung Cancer
Celecoxib in Treating Patients With Early-Stage Head and Neck Cancer or Non-Small Cell Lung Cancer
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of celecoxib may be an effective way to prevent the recurrence of stage I or stage II head and neck…
- Trial name
- NCT00058006
- Testing
- celecoxib, adjuvant therapy
- Where
- 4 sites in United States
- Sponsor
- Northwestern University
Head and Neck Cancer, Lymphedema
Developing a Checklist of Lymphedema Symptoms in Patients With Head and Neck Cancer
RATIONALE: Developing a symptom checklist for late-effect lymphedema may help doctors learn more about lymphedema in patients with head and neck cancer and plan the best treatment.
- Trial name
- NCT00840814
- Where
- 3 sites in United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Background: Head and neck cancers (HNCs) account for about 5% of all cancers worldwide. They grow in the mouth, throat, nasal cavity, or salivary glands. Prostate cancer is the most common cancer in men in the United States.
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Paranasal Sinus Neoplasms, Nasopharyngeal Carcinoma
- Trial name
- NCT07667400
- Testing
- SX-682, DTX
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Oral Mucositis, Osteoradionecrosis
Photobiomodulation in Oral Lesions Resulting From Anti-neoplastic Prevention
Introduction: There are several manifestations in the oral mucosa resulting from antineoplastic treatments by chemo (QT) or radiotherapy (RT).
- Conditions
- Oral Mucositis, Osteoradionecrosis, Osteonecroses, Bisphosphonate, Osteonecrosis Due to Drugs, Jaw
- Trial name
- NCT04717765
- Testing
- Preventive, LLL Phototherapy and topical Vit E, Curative, LLL Phototherapy and topical Vit E, Preventive, LLL Phototherapy and LPRF
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- University of Santiago de Compostela
Xerostomia, Hyposalivation
A New Oral salIvary equivAlent Compared to Two moisturizinG Mouth sprAys in Patients With xeRostomiA: NIAGARA Study
The purpose of this study is to evaluate the clinical efficacy, safety and acceptability of our new oral salivary equivalent in the relief of signs and symptoms related to mouth dryness as compared to two distinct moisturizing…
- Conditions
- Xerostomia, Hyposalivation, Head and Neck Cancer, Sjögren Syndrome
- Trial name
- NIAGARA (NCT02049112)
- Testing
- Salivary equivalent, Aequasyal, Biotene
- Where
- France
- Volunteers
- 210 people
- Sponsor
- Unither Pharmaceuticals, France
Salivary Gland Cancer
Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC
(1) To apply Bayesian statistics to screen for the most effective treatment regimen containing recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent vedicitumomab (Edisil, RC48) for locally advanced or…
- Trial name
- NCT05898373
- Testing
- vedicitumomab (Edisil, RC48）, vedicitumomab in combination with pyrrolizidine, RC48 in combination with a platinum-based chemotherapeutic agent
- Volunteers
- 120 people
- Sponsor
- Peking Union Medical College
Prostatic Neoplasms
Correlation Between PSA Levels and F-18 PSMA PET/CT Findings in Prostate Cancer Patient
It is a cross sectional study aimed to correlate between PSA Levels and F-18 PSMA PET/CT Scan findings and to evaluate the impact of PET/CT findings on the patient management
- Trial name
- NCT06209853
- Testing
- PSMA PET/CT
- Where
- Egypt
- Volunteers
- 59 people
- Sponsor
- Assiut University
Cancer
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00101972
- Testing
- monoclonal antibody RAV12
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- MacroGenics